Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Neurology | Family Medicine
Alzheimer's Disease Clinical Trials
A listing of Alzheimer's Disease medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.
Arizona
Sun City : Banner Sun Health Research Institute
A Phase 2, randomized, double-dummy, double-blind, placebo-controlled study to assess the efficacy, safety,and tolerability of AVP-923 (dextromethorphan/quinidine) for the treatment of symptoms of agitation in patients with Alzheimer’s disease.
Sun City : Banner Sun Health Research Institute
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease
Sun City : Banner Sun Health Research Institute
A randomized, multicenter, multicountry study to evaluate the effectiveness of Florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between florbetapir (18F) PET scan status and cognitive decline
Sun City : Banner Sun Health Research Institute
Alzheimer's Disease Neuroimaging Initiative 2 (ADNI2)
Sun City : Banner Sun Health Research Institute
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer ’s Disease or Mild Alzheimer's Disease
View More »
Goodyear : Call for Information (Investigational Site 0002)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Phoenix :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Phoenix : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Phoenix :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Phoenix : Banner Alzheimer Institute
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Scottsdale : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Sun City : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Sun City :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Sun City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Tucson : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
California
Encino : Pharmacology Research Institute, Encino
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients with Moderate to Severe Alzheimer's Disease
Encino : Pharmacology Research Institute, Encino
Study of an investigational medication for the treatment of Alzheimer's Disease
Fresno : The Margolin Brain Institute
Research study for treatment of symptoms of agitation in patients with Alzheimer’s disease.
Fresno : The Margolin Brain Institute Updated
Study in mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia.
Glendale : California Clinical Trials Medical Group, Inc.
Alzheimer's Disease Study
Los Alamitos : Pharmacology Research Institute, Los Alamitos
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients with Moderate to Severe Alzheimer's Disease
Los Alamitos : Pharmacology Research Institute, Los Alamitos
Study of an investigational medication for the treatment of Alzheimer's Disease
Newport Beach : Pharmacology Research Institute, Newport Beach
Study of an investigational medication for mild to moderate Alzheimer's Disease
Newport Beach : Pharmacology Research Institute, Newport Beach
Study of an investigational medication for the treatment of Alzheimer's Disease
Sacramento : Sutter Institute for Medical Research (SIMR)
Mild Cognitive Impairment
Santa Ana : Apex Research Institute
Alzheimers? Be a Part of Research.
Santa Rosa : Radiant Research - Santa Rosa
Alzheimer's Disease Research Study
Sherman Oaks : California Neuroscience Research Medical Group, Inc.
Clinical research study of an investigational medication vs. placebo for agitation
in persons with Alzheimer’s disease.
View More »
Aliso Viejo : Avanir Pharmaceuticals
PRISM Registry: Pseudobulbar Affect Registry Series
Costa Mesa : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Encino : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Escondido : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Fountain Valley :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Fresno :
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
Fresno :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Fullerton : Call for Information (Investigational Site 0079)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Glendale : California Clinical Trials Medical Group, Inc.
Evaluation of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease
Glendale : Glendale Adventist Medical Center
Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease
Lomita :
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Long Beach :
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Long Beach : Call for Information (Investigational Site 0053)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Long Beach : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Long Beach : Site Reference ID/Investigator# 69602
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Long Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Los Alamitos : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Los Angeles :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
San Diego :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
San Francisco :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
San Francisco : Site Reference ID/Investigator# 66527
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
San Francisco : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
San Francisco : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Sherman Oaks :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Valencia : Sanguine Biosciences
A Biospecimen and Clinical Data Study on Patients With Alzheimer's, Multiple Sclerosis, Parkinson's, and Huntington's, for Drug & Biomarker Discovery
Colorado
Connecticut
Waterbury : Chase Medical Research, LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E4 Non-Carriers.
View More »
Hamden : Site Reference ID/Investigator# 66530
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Hamden : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
New Haven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Norwalk : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Florida
Hallandale Beach : MD Clinical
Is your memory loss just a sign of age, or something else?
Miami : Research Site Updated
Alzheimer’s Research Study ITN# 12038
Miami : Research Site Updated
Alzheimer's Disease ITN# 12129
Ocala : Renstar Medical Research
Alzheimer's Disease
St. Petersburg : Comprehensive Clinical Development - St. Petersburg, FL
Alzheimer’s Disease ITN# 12032
St. Petersburg : Meridien Research
Alzheimer's Disease
Tampa : Axiom Clinical Research of Florida
A clinical research study for patients with Mild Alzheimer's Disease
View More »
Boca Raton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Brooksville : Meridien Research
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Brooksville :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Brooksville : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Clearwater : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Deerfield Beach :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Deerfield Beach : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Delray Beach : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Delray Beach : Site Reference ID/Investigator# 56503
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Delray Beach : Site Reference ID/Investigator# 66522
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Delray Beach : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Delray Beach : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Delray Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Delray Beach : Site Reference ID/Investigator# 84178
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
Delray Beach : Site Reference ID/Investigator# 73493
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Fort Myers :
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
Fort Myers : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Fort Myers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Hallandale Beach :
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Hallandale Beach : Call for Information (Investigational Site 0059)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Hallandale Beach : MD Clinical
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Hallandale Beach : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
Hallandale Beach :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Hallandale Beach : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Hallendale Beach : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Hollywood : Call for Information (Investigational Site 0063)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Miami : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Miami :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Ocala : Call for Information (Investigational Site 0058)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Ocala : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Orlando :
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Orlando : Call for Information (Investigational Site 0018)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Orlando : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Orlando : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Orlando : Site Reference ID/Investigator# 66524
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Orlando : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Orlando :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Orlando : Compass Research
Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease
Palm Beach Gardens : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Sarasota : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Sunrise : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Sunrise :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Tampa :
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Tampa :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Tampa : Site Reference ID/Investigator# 66531
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Tampa : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Tampa : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
West Palm Beach : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
West Palm Beach :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
West Palm Beach : Site Reference ID/Investigator# 56514
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
West Palm Beach : Site Reference ID/Investigator# 66529
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
West Palm Beach : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
West Palm Beach : Site Reference ID/Investigator# 73496
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Weston :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Georgia
Atlanta : NeuroTrials Research
New Alzheimer’s Disease Research
View More »
Atlanta : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
Atlanta : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Decatur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Savannah : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Illinois
Elk Grove Village : Alexian Brothers Hospital Network
A multinational, multicenter, randomized, double-blind, parallel-group, placebo- controlled study of the effect on cognitive performance, safety, and tolerability of SAR110894D at the doses of 0.5 mg, 2 mg, and 5 mg/day for 24 weeks in patients with mild to moderate Alzheimer's Disease on stable donepezil therapy
Elk Grove Village : Alexian Brothers Hospital Network
A phase 2 multicenter, double-blind, placebo controlled, parallel group study of PF-04447943 in subjects with mild to moderate Alzheimer's Disease on stable Donepezil therapy.
Elk Grove Village : Alexian Brothers Hospital Network
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Efficacy and Safety Trial of Bapineuzumab (AAB-001) in Subjects with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E e4 Carriers
Elk Grove Village : Alexian Brothers Hospital Network
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of MABT5102A in Patients with Mild to Moderate Alzheimer’s Diseases
View More »
Elk Grove :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Elk Grove Village :
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
Elk Grove Village : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Elk Grove Village :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Elk Grove Village : Site Reference ID/Investigator# 62611
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Elk Grove Village : Site Reference ID/Investigator# 66526
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Kentucky
Louisiana
Baton Rouge : Call for Information (Investigational Site 0043)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Shreveport : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Massachusetts
Boston : Beth Israel Deaconess Medical Center
Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients
Chestnut Hill : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Plymouth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Quincy : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Qunicy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Michigan
Kalamazoo : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
Kalamazoo : Pfizer Investigational Site
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
Mississippi
Hattiesburg : Hattiesburg Clinic Neurological Research Center
Mayflower: A phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to investigate the efficacy and safety of RO4602522 added to the background therapy of the acetylcholinesterase inhibitors Donepezil or Rivastigmine in patients with moderate severity Alzheimer’s Disease
View More »
Flowood : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
Missouri
Creve Coeur : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
Creve Coeur : Pfizer Investigational Site
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
St. Louis : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
St. Louis : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
St. Louis : Pfizer Investigational Site
Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease
Nevada
Las Vegas : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Las Vegas :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
New Jersey
Stratford : University of Medicine and Dentistry of New Jersey - School of Osteopathic Medicine
Alzheimer's disease study for mild to moderate AD.
View More »
Eatontown : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Eatontown : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
Edison : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
Marlton :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Monroe Township : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Oakhurst : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
Princeton : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Summit :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Toms River :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Toms River : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
New York
New Hyde Park : Parker Jewish Institute
This study will investigate the safety and efficacy of immune globulin intravenous, for the treatment of mild to moderate Alzheimer's Disease.
New York : Biomedical Research Alliance of New York
People with Alzheimer’s disease are asked to participate in a research study being conducted by North Shore-Long Island Jewish Health System.
View More »
Albany :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
Albany : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Orangeburg :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Patchogue : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Rochester : Call for Information (Investigational Site 0089)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Rochester : Call for Information (Investigational Site 0039)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Rochester :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Staten Island : Site Reference ID/Investigator# 56506
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Staten Island : Site Reference ID/Investigator# 66525
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
North Carolina
Greensboro : Guilford Neurologic Associates
Impact of Florbetapir F 18 PET on the Clinical Diagnosis and Management of Patients With Progressive Cognitive Decline
Raleigh : Multi-Specialty Research Associates of NC
Is Alzheimer’s Disease affecting your loved one?
Winston-Salem : PMG Research of Winston-Salem
Do you care for someone afflicted with Alzheimer's Disease?
Winston-Salem : PMG Research of Winston-Salem
MEMORIES MATTER! Is Alzheimer's Disease taking away the enjoyment in your life?
View More »
Charlotte : Call for Information (Investigational Site 0013)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Durham : Duke Health Center at Morreene Road
Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias
Durham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Greensboro : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Winston-Salem : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Ohio
Beechwood : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Canton :
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
Centerville :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Cleveland :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Columbus :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
View More »
Dayton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Lakewood :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Toledo : Research Site
Multiple Dose Study of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease.
Oklahoma
Oklahoma City : Call for Information (Investigational Site 0027)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Oklahoma City : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Tulsa : Call for Information (Investigational Site 0055)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Oregon
Pennsylvania
Abington : Call for Information (Investigational Site 0081)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Jenkintown : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Rhode Island
East Providence :
A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Providence : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
South Carolina
Greer : Radiant Research - Greer
Clinical Research Study for Alzheimer's Disease
View More »
North Charleston :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Tennessee
Nashville : Clinical Research Associates, Inc.
Alzheimer's Disease Research Study
View More »
Cordova : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Kingsport : Call for Information (Investigational Site 0049)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Texas
Dallas : Texas Neurology, PA
Alzheimer's Research Study
Dallas : Texas Neurology, PA
Mild Cognitive Impairment
View More »
Austin : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
DeSoto : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Houston :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
San Antonio :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
San Antonio : CEDRA Clinical Research, LLC
Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
Utah
Salt Lake City : Lifetree Clinical Research
Alzheimer's Research Study
Salt Lake City : CRI Lifetree
Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer ’s Disease or Mild Alzheimer's Disease
Salt Lake City : CRI Lifetree
The objectives of the study are to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of AVP-923 compared to placebo, for the treatment of symptoms of agitation in patients with AD.
Salt Lake City : CRI Lifetree
To assess the safety, tolerability, and the effects of of BMS-241027 on CSF Tau Nterminal domain fragment in subjects with mild Alzheimer’s Disease (AD).
Salt Lake City : CRI Lifetree
To evaluate the effect of gantenerumab vs. placebo on the change in the Clinical Dementia Rating scale Sum of Boxes (CDR-SOB), a global measure of cognition and functional ability
View More »
Salt Lake City :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Salt Lake City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Vermont
Bennington : Research Site
Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline
Bennington :
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Bennington : Site Reference ID/Investigator# 66523
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Burlington : Fletcher Allen Health Care-Clinical Neuroscience Research Unit
Quetiapine for the Treatment of Insomnia in Alzheimer's Disease
Virginia
Richmond : Call for Information (Investigational Site 0062)
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Washington
Bellevue : Elan Investigational Site
Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Wisconsin
Waukesha : Pfizer Investigational Site
Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil
Australia
Randwick : GSK Investigational Site
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers
Canada
Gatineau : Site Reference ID/Investigator# 71793
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Medicine Hat :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Montreal : Site Reference ID/Investigator# 71794
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Peterborough : Site Reference ID/Investigator# 71798
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Toronto :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
View More »
Toronto : Site Reference ID/Investigator# 71795
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Verdun : Site Reference ID/Investigator# 71796
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
China
Baoding : Hebei mental health center
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Beijing : Novartis Investigative Site
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
Beijing : Peking University Institute of Mental Health
Memantine on Aggression and Agitation of Alzheimer's Disease (AD)
Beijing : Beijing HuiLongGuan Hospital
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Beijing : Beijing Shijitan Hospital, EMU
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
View More »
Changchun : The first Affiliated Hospital of Jilin University
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Guangzhou : Guangzhou Brain Hospital
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Guilin : Affiliated Hospital of Guilin Medical University
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Hangzhou : The First Affiliated Hospital of Medical School of Zhejiang University
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Kunming : First Affiliated Hospital of Kunming Medical University
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Nanjing : Jiangsu Province Hospital
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Shanghai : Shanghai Mental Health Center
Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease
Shanghai : Shanghai Tenth People's hospital
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Shanghai : Shanghai
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Shanghai : Shanghai Changzheng Hospital
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Shanghai : Shanghai First People's Hospital
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
Czech Republic
Chocen : Policlinic
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Kladno : BRAIN-SOULTHERAPY s.r.o.
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Litoměřice : Bialbi.s.r.o. Psychiatrické oddělení
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Olomouc : Vojenska Nemocnice Psychiatricke oddeleni
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Olomouc : Psychiatricka Ambulance
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
View More »
Praha : Clintrial
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Praha : PRAGTIS s.r.o.
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Prerov : Psychosocialni centrum
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
France
Aix En Provence : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Bordeaux :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Caen : CHU de la Côte de Nacre
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Cahors : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Castres : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
View More »
Clermont-Ferrand : CHU Clermont-Ferrand
Alzheimer and Sleep
Courbevoie : Laboratoires Merck Sharp & Dohme - Chibret
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Dijon Cedex : Site Reference ID/Investigator# 71573
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Foix Cedex : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Lavaur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Léon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Lille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Limoges : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Limoges Cedex : Site Reference ID/Investigator# 77833
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Marseille : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Marseille : Hôpital Sainte-Marguerite
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Montauban Cedex : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Montpellier cedex : CHU Gui de Chauliac
Hippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers
Nancy : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Nantes : Hôpital Guillaume et René Laennec
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Nice :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Nice : Hôpital de l'Archet
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Paris :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Paris :
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
Paris : Pitié-Salpêtrière Hospital
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Paris : Pitié-Salpêtrière Hospital - Centre du Langage et de Neuropsychologie
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Paris : Pitié-Salpêtrière Hospital - Fédération de Neurologie
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Paris : Site Reference ID/Investigator# 68706
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Paris Cedex 10 : Site Reference ID/Investigator# 68704
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Rennes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Rennes : Hôpital Pontchaillou
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Rouen : Hôpital Charles Nicolle
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Saint-Brieuc : Centre Hospitalier
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Saint-Etienne : Hôpital Bellevue
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Strasbourg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Strasbourg : Hôpital Civil
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Toulouse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Toulouse :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Toulouse :
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
Tours : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Tours Cedex 9 :
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
Vic-En-Bigorre : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Non-drug Methods Study in Patients With Alzheimer's Disease
Germany
Berlin :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Berlin : Site Reference ID/Investigator# 68768
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Erlangen :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Frankfurt :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Freiburg : Site Reference ID/Investigator# 68764
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
View More »
Huettenberg : Site Reference ID/Investigator# 68767
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Mittweida : Site Reference ID/Investigator# 69960
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Muenchen :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Munich : Site Reference ID/Investigator# 68765
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Schwerin : Site Reference ID/Investigator# 69959
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Siegen :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Greece
Athens : Site Reference ID/Investigator# 68732
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Athens : Site Reference ID/Investigator# 68730
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Haidari, Athens : Site Reference ID/Investigator# 68731
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Thessaloniki : Site Reference ID/Investigator# 68735
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Thessaloniki : Site Reference ID/Investigator# 68729
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Israel
Tel Aviv : Merchav Clinics
Deep Transcranial Magnetic Stimulation for Treatment of Alzheimer's Disease
Tel Aviv : Tel Aviv Sourasky Medical Center, Neurology Department
Deep Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease
Italy
Japan
Anjo-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Azumino-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Bunkyo-ku : Pfizer Investigational Site
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Fukui-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Fukuoka-city : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
View More »
Fukuoka-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Hachioji-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Kamakura-city : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Kamakura-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Kansai : Kansai region
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients
Kanto : Kanto region,
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients
Kanto :
Safety and Efficacy of MT-4666
Kasukabe-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Kawasaki-city : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Kawasaki-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Kita-gun : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Kitamorokata-gun : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Koshi-city : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Koshi-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Koshigaya-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Kumamoto City : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Kyoto : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Kyoto-city : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Kyoto-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Kyushu : Kyushu region
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients
Miyoshi-city : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Miyoshi-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Musashino-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Nagoya : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Ohtake : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Osaka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Sagamihara : Pfizer Investigational Site
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Sapporo-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Setagaya-ku : Pfizer Investigational Site
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Suita-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Suwa : Pfizer Investigational Site
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Toakai : Tokai region
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients
Tohoku : Tohoku region
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer's Disease Patients
Tokyo : MSD K.K.
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
Toon-city : Novartis Investigative Site
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Yokohama : Novartis Investigative Site
Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors
Korea, Republic of
Goyang : National Health Insurance Corporation Ilsan Hospital
Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease
Incheon : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
Seongnam-si : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
Seoul : SKChemicals invetigational site
A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease
Seoul : Samsung Medical Center
Clinical Trial of Donepezil Between the Naive Group and the Switching Group
View More »
Seoul : Pfizer Investigational Site
Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease
Seoul : Kyung Hee University Oriental Medicine Hospital
Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease
Seoul : The Catholic University of Korea, Seoul St. Mary's Hospital
Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease
Seoul City : Samsung Medical Center
Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia
Suwon : The Catholic University of Korea, St. Vincent's Hospital
Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease
Netherlands
Poland
Gdynia : Site Reference ID/Investigator# 62565
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Poznan : Site Reference ID/Investigator# 62563
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Szczecin : Site Reference ID/Investigator# 62562
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Romania
Arad : Spitalul Judetean de Urgenta Arad, Clinica de Psihiatrie
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Focsani : Spitalul de Urgenta "SF. Pantelimon" Focsani
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Iasi : Spitalul Clinic de Psihiatrie Socola Iasi
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Oradea : Crucea Alba - Dr. Oros si Asociatii - Societate Civila Medicala
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Sibiu : Spitalul Clinic Judetean de Urgenta SIBIU
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
View More »
Sibiu : Spitalul de Psihiatrie Sibiu
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Timisoara : Spitalul Clinic Judetean de Urgenta, Clinica Psihiatrie
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Timisoara : Spitalul Clinic Judetean de Urgenta, Clinica Neurologie 2
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Russian Federation
Kazan : Site Reference ID/Investigator# 60955
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Kazan : Site Reference ID/Investigator# 60945
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Kirov : Site Reference ID/Investigator# 60954
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Moscow : Site Reference ID/Investigator# 60959
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Moscow : Site Reference ID/Investigator# 60951
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
View More »
Novosibirsk : Site Reference ID/Investigator# 60946
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Saratov : Site Reference ID/Investigator# 60950
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
St. Petersburg : Site Reference ID/Investigator# 60952
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
St. Petersburg : Site Reference ID/Investigator# 60947
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
St. Petersburg : Site Reference ID/Investigator# 60949
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
St. Petersburg : Site Reference ID/Investigator# 60958
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Slovakia
Banska Bystrica : Neurologicka Ambulancia, s.r.o.
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Bratislava : Univerzitna nemocnica Bratislava, Geronto-psychiatrické oddelenie
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Dubnica nad Váhom : KONZILIUM s.r.o.
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Krompachy : Neurologická ambulancia
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
South Africa
Belville : Site Reference ID/Investigator# 60911
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Belville : Site Reference ID/Investigator# 67586
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Belville : Site Reference ID/Investigator# 73507
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Cape Town : Site Reference ID/Investigator# 67582
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
George : Site Reference ID/Investigator# 60912
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
View More »
George : Site Reference ID/Investigator# 67584
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
George : Site Reference ID/Investigator# 73505
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Johannesburg : Site Reference ID/Investigator# 60910
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Johannesburg : Site Reference ID/Investigator# 67585
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Johannesburg : Site Reference ID/Investigator# 73506
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Rosebank : Site Reference ID/Investigator# 67583
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Spain
Barcelona : Funcació ACE
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
Barcelona :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Barcelona :
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
Elche :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Granada : Clinical Nutrition and Dietetic Unit, University Hospital Virgen de las Nieves
Evaluation of a Diet in Patients With Senile Dementia
View More »
Granada : Department of Biochemistry and Molecular Biology II. University of Granada
Evaluation of a Diet in Patients With Senile Dementia
Madrid :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Madrid : Merck Sharp and Dohme de Espana S.A.
An Efficacy and Safety Trial of MK-8931 in Mild to Moderate Alzheimer's Disease (P07738 AM3)
Sevilla :
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
Ukraine
Dnipropetrovsk : Dnipropetrovsk Regional Clinical Hospital
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Donetsk : Donetsk Regional Clinical Psychiatric Hospital
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Donetsk : Site Reference ID/Investigator# 60909
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Kharkiv : Central Clinical Hospital Ukrzaliznytsi
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Kiev : Site Reference ID/Investigator# 60906
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
View More »
Kyiv : Department of Age Physiology and Pathology of Nervous System; Institute of Gerontology NAMS
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Lugansk : Lugansk Regional Clinical Psychoneurological Hospital
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Lviv : Lviv National Medical University named after Galytskyy
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Odessa : Odessa Regional Psychiatric Hospital # 2
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Odessa : Odessa Regional Psychoneurology Dispensary
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Poltava : Poltava Regional Clinical Psychiatric Hospital
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Poltava : Site Reference ID/Investigator# 60905
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Stepanovka : Department #3 of the Kherson Regional Psychiatric Hospital
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
United Kingdom
Bath : Site Reference ID/Investigator# 60960
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Bath : Site Reference ID/Investigator# 67787
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Blackburn : Site Reference ID/Investigator# 60963
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Blackburn : Site Reference ID/Investigator# 73503
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
Bradford : MAC Clinical Research
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
View More »
Cambridge : GSK Investigational Site
Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects
Crowborough : Grove House
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
Glasgow : Site Reference ID/Investigator# 60962
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
Glasgow : Site Reference ID/Investigator# 67784
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Glasgow : Site Reference ID/Investigator# 73501
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease.
London : Site Reference ID/Investigator# 60961
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
London : Site Reference ID/Investigator# 67786
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Manchester : Site Reference ID/Investigator# 67785
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Oxford : Warneford Hospital
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
Southampton : Memory Assessment and Research Centre, Moorgreen Hospital
Safety and Tolerability of Etanercept in Alzheimer's Disease
Staffordshire : MAC Clinical Research
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
Warrington : Site Reference ID/Investigator# 67783
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
